Patent Challenges Via IPR Still Pretty Scary, Even After Acorda's Win

Reform efforts gain steam, but hedge fund manager Kyle Bass' attack on Acorda's patents was denied based on specifics of prior art, not biotech's arguments about abuse of the system.